Clinical trials: Metastatic Melanoma, open to volunteers
Melanoma, In-Transit Metastasis
Evaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion
To evaluate safety and the effect of isolated limb perfusion together with nivolumab as a way to increase efficacy and give further insights in early immunological mechanisms.
- Trial name
- NivoILP (NCT03685890)
- Testing
- Nivolumab, Isolated limb perfusion (ILP)
- Where
- 4 sites in Netherlands, Sweden
- Volunteers
- 74 people
- Sponsor
- Vastra Gotaland Region
Sarcoma, Synovial, Sarcoma,Soft Tissue
Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
A Phase I/II Dose Escalation, Safety and Efficacy Study of HBI 0201-ESO TCRT (anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes) Given by Infusion to Patients with NY-ESO-1 -Expressing Metastatic Cancers
- Conditions
- Sarcoma, Synovial, Sarcoma,Soft Tissue, Melanoma Stage IV, Triple Negative Breast Cancer
- Trial name
- NCT05296564
- Testing
- CYCLOPHOSPHAMIDE and FLUDARABIN, Cyclophosphamide, HBI 0201-ESO TCRT
- Where
- Israel
- Volunteers
- 3 people
- Sponsor
- Hadassah Medical Organization
Tumor Skin, Metastatic Melanoma
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
This is a study to investigate the safety and efficacy of an investigational OBX-115 regimen in adult participants with advanced solid tumors.
- Conditions
- Tumor Skin, Metastatic Melanoma, Melanoma, Lung Cancer
- Trial name
- Agni-01 (NCT06060613)
- Testing
- OBX-115
- Where
- 14 sites in United States, Australia
- Volunteers
- 254 people
- Sponsor
- Obsidian Therapeutics, Inc.
Metastatic Melanoma, Skin Cancer
Cryoablation+Ipilimumab+Nivolumab in Melanoma
The aim of this study is to find out whether the combination of two approved drugs, ipilimumab and nivolumab, in combination with cryoablation are safe and effective for participants who have an unresectable melanoma that is…
- Trial name
- NCT05779423
- Testing
- Ipilimumab, Nivolumab, Cryoablation
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Massachusetts General Hospital
Metastatic Uveal Melanoma, Cutaneous Melanoma
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including…
- Conditions
- Metastatic Uveal Melanoma, Cutaneous Melanoma, Colorectal Cancer, Other Solid Tumors
- Trial name
- NCT03947385
- Testing
- IDE196, Binimetinib, Crizotinib
- Where
- 15 sites in United States, Australia and 1 more
- Volunteers
- 336 people
- Sponsor
- IDEAYA Biosciences
Melanoma (Skin)
Immunological Functionnal Test Validation to Predict Melanoma Metastatic Patient Response to Checkpoint Inhibitors
Checkpoint inhibitor such as anti-CTLA-4 and anti-PD-1 are known to block inhibitory signals and increase the immune antimutoral response.
- Trial name
- mela-quantif (NCT05649683)
- Testing
- Evaluation of cytokine production
- Where
- 3 sites in France
- Volunteers
- 60 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Mestastatic Uveal Melanoma
Neoadjuvant Tebentafusp in Patients With Metastatic Uveal Melanoma
Uveal melanoma (UM) is a rare type of melanoma, with an incidence of 4.4 cases per million in Europe each year. During recent years, different treatment approaches have been tested in patients with metastatic UM.
- Trial name
- NEO-TB (NCT07057596)
- Testing
- Tebentafusp
- Where
- 4 sites in Germany, Spain
- Volunteers
- 19 people
- Sponsor
- Grupo Español Multidisciplinar de Melanoma
Melanoma Metastatic
T-cell Therapy with CRISPR PD1-edited Tumor Infiltrating Lymphocytes for Patients with Metastatic Melanoma
The purpose of this study is to assess wether it is safe and feasible to treat patients with tumor infiltrating lymphocytes that have been silenced for PD-1, using CRISPR-Cas9.
- Trial name
- CRISPR-TIL (NCT06783270)
- Testing
- TIL therapy
- Where
- Denmark
- Volunteers
- 10 people
- Sponsor
- Inge Marie Svane
Cancer, Melanoma Stage III
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
KB707-01 is a Phase 1/2, open-label, multicenter, dose escalation and expansion study. The study will evaluate the safety and tolerability of KB707 in adults with locally advanced or metastatic solid tumors who have progressed on…
- Conditions
- Cancer, Melanoma Stage III, Melanoma Stage IV, Cutaneous Melanoma
- Trial name
- NCT05970497
- Testing
- KB707, Opdualag, KEYTRUDA ®( Pembrolizumab)
- Where
- 15 sites in United States
- Volunteers
- 240 people
- Sponsor
- Krystal Biotech, Inc.
Melanoma Stage III, Melanoma Stage IV
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
The purpose of this study is to determine if neoadjuvant (treatment before surgery) immunotherapy treatment based on tumor biomarkers results in better participant outcomes.
- Conditions
- Melanoma Stage III, Melanoma Stage IV, Advanced Melanoma, Melanoma
- Trial name
- NCT06295159
- Testing
- Nivolumab, Nivolumab + Relatlimab, Ipilimumab
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Metastatic Uveal Melanoma, Metastatic Uveal Melanoma in the Liver
Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma
The purpose of this study is to determine the effects (good and bad) that Tebentafusp in combination with Yttrium-90 (Y-90) radioembolization has on patients with metastatic uveal melanoma that has spread to the liver.
- Trial name
- NCT06627244
- Testing
- Tebentafusp, TheraSphere™ Yttrium-90 Trans-Arterial Radioembolization
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Miami
Melanoma Stage IV
Urinary Microbiome as a Biomarker for Melanoma Diagnosis and Response Prediction to Systemic Tumour Therapy
This study looks at whether the bacteria naturally present in urine (the "urinary microbiome") can help doctors better understand melanoma, a type of skin cancer, and predict how well patients respond to treatment.
- Trial name
- NCT07635732
- Where
- Austria
- Volunteers
- 50 people
- Sponsor
- Medical University of Graz
Melanoma Stage III, Melanoma Stage IV
Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma
The purpose of this study is to determine how beta-glucan affects the immune system in subjects with melanoma.
- Trial name
- NCT04513028
- Testing
- Beta-Glucan
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Kelly McMasters
Advanced Solid Tumor, Uveal Melanoma, Metastatic
Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours
The Phase I trial is evaluating safety, tolerability, pharmacokinetics and preliminary efficacy of MBS8(1V270) in subjects with advanced solid tumours.
- Conditions
- Advanced Solid Tumor, Uveal Melanoma, Metastatic, Cutaneous Melanoma
- Trial name
- NCT04855435
- Testing
- MBS8(1V270), MBS8(1V270) and pembrolizumab combination
- Where
- 5 sites in Denmark, Spain
- Volunteers
- 106 people
- Sponsor
- MonTa Biosciences ApS
Melanoma (Skin)
Identification of Metabolic Phenotypes Associated With Melanoma Metastasis
The goal of this study is to observe metabolic features associated with human melanoma tumors.
- Trial name
- NCT06400550
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- University of Texas Southwestern Medical Center
Melanoma Metastatic
Stereotactic Ablative Radiotherapy (XRT) and Immunotherapy for Oligometastatic Extracranial Melanoma
The purpose of this research is to evaluate the addition of radiotherapy to the standard immunotherapy drugs that are given to patients with advanced or metastatic melanoma that has spread to other parts of the body.
- Trial name
- AXIOM (NCT06767306)
- Testing
- Stereotactic Body Radiotherapy (extracranial) concurrent with Immunotherapy, Immunotherapy alone
- Where
- 5 sites in Australia, Canada
- Volunteers
- 129 people
- Sponsor
- Melanoma Institute Australia
Melanoma (Skin) Stage IV
Cryoablation Combined With Hepatic Arterial Infusion of Iparomlimab and Tuvonralimab (QL1706), Intravenous Dacarbazine, and Oral Lenvatinib in Patients With Liver Metastases From Malignant Melanoma: a Single-arm, Phase II, Prospective Trial
To explore the efficacy and safety of cryoablation combined with hepatic arterial infusion of iparomlimab and tuvonralimab, intravenous dacarbazine, and oral lenvatinib in patients with liver metastases from malignant melanoma.
- Trial name
- Cryo-IA-Check (NCT07847359)
- Testing
- Cryoablation, Iparomlimab and Tuvonralimab, Dacarbazine
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Sun Yat-sen University
Melanoma, Solid Tumors
A Study of BL-M08D in Patients With Locally Advanced or Metastatic Melanoma and Other Solid Tumors
This Phase Ib/II study is a clinical study to explore the efficacy and safety of BL-M08D1 for injection in patients with locally advanced or metastatic melanoma and other solid tumors.
- Trial name
- NCT07841925
- Testing
- BL-M08D1
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Melanoma Metastatic, NRAS Mutation
Tunlametinib in Combination With Pucotenlimab and Hydroxychloroquine in NRAS Mutant Melanoma
This study evaluates the combination of the autophagy inhibitor hydroxychloroquine (HCQ), the MEK inhibitor tunlametinib, and the anti-PD-1 antibody pucotenlimab in patients with locally advanced or metastatic melanoma.
- Trial name
- NCT07750067
- Testing
- Tunlametinib, Pucotenlimab, Hydroxychloroquine (HC)
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Sun Yat-sen University
Colorectal Cancer, Ovarian Cancer
Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors
This study is based on the finding that tumor cells that are grown in the laboratory can be modified in such a way that, when injected to the patient, they will stimulate his/her immune response.
- Conditions
- Colorectal Cancer, Ovarian Cancer, Gastric Cancer, Breast Cancer
- Trial name
- NCT00722228
- Testing
- Autologous or Allogeneic tumor cells
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Hadassah Medical Organization